Vitreous Detachment

What is vitreous detachment?

Most of the eye's interior is filled with vitreous, a gel-like substance that helps the eye maintain a round shape. There are millions of fine fibers intertwined within the vitreous that are attached to the surface of the retina, the eye's light-sensitive tissue. As we age, the vitreous slowly shrinks, and these fine fibers pull on the retinal surface. Usually the fibers break, allowing the vitreous to separate and shrink from the retina. This is avitreous detachment.
In most cases, a vitreous detachment, also known as a posterior vitreous detachment, is not sight-threatening and requires no treatment.

Risk Factors

Who is at risk for vitreous detachment?

A vitreous detachment is a common condition that usually affects people over age 50, and is very common after age 80. People who are nearsighted are also at increased risk. Those who have a vitreous detachment in one eye are likely to have one in the other, although it may not happen until years later.

Symptoms and Detection

What are the symptoms of vitreous detachment?

As the vitreous shrinks, it becomes somewhat stringy, and the strands can cast tiny shadows on the retina that you may notice as floaters, which appear as little "cobwebs" or specks that seem to float about in your field of vision. If you try to look at these shadows they appear to quickly dart out of the way.
One symptom of a vitreous detachment is a small but sudden increase in the number of new floaters. This increase in floaters may be accompanied by flashes of light (lightning streaks) in your peripheral, or side, vision. In most cases, either you will not notice a vitreous detachment, or you will find it merely annoying because of the increase in floaters.

How is vitreous detachment detected?

The only way to diagnose the cause of the problem is by a comprehensive dilated eye examination. If the vitreous detachment has led to a macular hole or detached retina, early treatment can help prevent loss of vision.

Treatment

How does vitreous detachment affect vision?

Although a vitreous detachment does not threaten sight, once in a while some of the vitreous fibers pull so hard on the retina that they create amacular hole to or lead to a retinal detachment. Both of these conditions are sight-threatening and should be treated immediately.
If left untreated, a macular hole or detached retina can lead to permanent vision loss in the affected eye. Those who experience a sudden increase in floaters or an increase in flashes of light in peripheral vision should have an eye care professional examine their eyes as soon as possible.

Future Treatment for Nearsightedness - Compact Fluorescent Light Bulbs?

ScienceDaily (May 8, 2012) - Researchers at the University of Alabama at Birmingham hope to one day use fluorescent light bulbs to slow Nearsightedness, which affects 40 percent of American adults and can cause blindness.

In an early step in that direction, results of a study found that small increases in daily artificial light slowed the development of Nearsightedness by 40 percent in tree shrews, which are close relatives of primates.

The team, led by Thomas Norton, Ph.D., professor in the UAB Department of Vision Sciences, presented the study results May 8 at the 2012 Association for Research in Vision and Ophthalmology annual meeting in Ft. Lauderdale.

People can see clearly because the front part of the eye bends light and focuses it on the retina in back. Nearsightedness, also called myopia, occurs when the physical length of the eye is too long, causing light to focus in front of the retina and blurring images.

Myopia has many causes, some related to inheritance and some to the environment. Research in recent years had, for instance, suggested that children who spent more time outdoors, presumably in brighter outdoor light, had less myopia as young adults. That raised the question of whether artificial light, like sunlight, could help reduce myopia development, without the risks of prolonged sun exposure, such as skin cancer and cataracts.

"Our hope is to develop programs that reduce the rate of myopia using energy efficient, fluorescent lights for a few hours each day in homes or classrooms," said John Siegwart, Ph.D., research assistant professor in UAB Vision Sciences and co-author of the study. "Trying to prevent myopia by fixing defective genes through gene therapy or using a drug is a multi-year, multimillion-dollar effort with no guarantee of success. We hope to make a difference just with light bulbs."

Sorting through theories

Work over 25 years had shown that putting a goggle over one eye of a study animal, one that lets in light but blurs images, causes the eye to grow too long, which in turn causes myopia. Other past studies had shown that elevated light levels could reduce myopia under these conditions, whether the light was produced by halogen lamps, metal halide bulbs or daylight. The current study is the first to show that the development of myopia can be slowed by increasing daily fluorescent light levels.

One prevailing theory on myopia-related shape changes in the eye is that they are caused by the blurriness of images experienced while reading or doing other near-work chores. Another holds some people develop myopia because they have low levels of vitamin D, which goes up with exposure to sunlight and could explain the connection between outdoor light and reduced myopia. A third theory, one reinforced by the current results, is that bright light causes an increase in levels of dopamine, a signaling molecule in the retina.

To test the theories, the team used a goggle that lets in light but no images to produce myopia in one eye of each tree shrew. They found that a group exposed to elevated fluorescent light levels for eight hours per day developed 47 percent less myopia than a control group exposed to normal indoor lighting, even though the images were neither more nor less blurry. They also found that animals fed vitamin D supplements developed myopia just like ones without the supplement. Given these results, the team is now experimenting with light levels and treatment times to see if a short, bright light treatment could be effective. They have also begun studies looking at the effect of elevated light on retinal dopamine levels as it relates to the reduction of myopia.

"If we can find the best kind of light, treatment period and light level, we'll have the scientific justification to begin studies raising light levels in schools, for instance," said Norton. "Compact fluorescent bulbs use much less electricity than standard light bulbs, and future programs raising light levels will have more impact the less expensive they are."

Other social bookmarking and sharing tools:

http://www.sciencedaily.com/releases/2012/05/120508163228.htm

Story Source:

The above story is reprinted from materials provided by University of Alabama at Birmingham, via Newswise. The original article was written by Greg Williams.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

How Does Nearsightedness Develop in Children?

ScienceDaily (Mar. 1, 2012) - Myopia (Nearsightedness) develops in children when the lens stops compensating for continued growth of the eye, according to a study in the March issue of Optometry and Vision Science, official journal of the American Academy of Optometry.

The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

Using detailed information on eye growth and vision changes in children over time, the new research shows "decoupling" of lens adaptation from eye growth about a year before myopia occurs. Donald O. Mutti, OD, PhD, of The Ohio State University College of Optometry, is lead author of the new study.

Growth Imbalance Leads to Myopia…

The researchers analyzed repeated measurements of vision and eye growth performed over several years in children aged 6 to 14. The study focused on the growth of the two key parts of the eye affecting normal vision: the cornea, the transparent front part that lets light into the eye; and the lens, located behind the cornea, which focuses light rays on the retina at the back of the eye.

Myopia or Nearsightedness -- difficulty seeing objects at a distance -- develops in about 34% of American children as they grow. Vision professionals and scientists typically think of myopia as a problem occurring when the eyeball becomes too long (front to back) for the optical power of the cornea and lens.

However, it has been unclear how this imbalance develops in children who previously had normal vision. To answer this question, Dr. Mutti and colleagues compared changes in eye growth for children who developed myopia at different ages versus those whose vision remained normal.

They found that, in children without myopia, the lens grew thinner and flatter to maintain normal vision as the eye grew. This adaptation maintained a normal balance between the optical power of the lens and the increasing length of the eyeball. From age nine months to nine years, eyeball length increased by an average of three millimeters.

...As Lens Stops Responding to Increasing Eye Length

However, in children who developed myopia, the lens stopped changing in response to eye growth. Nearsightedness developed not just because of increases in the length of the eyeball, but rather because the optical power of the lens no longer changed as the eye grew.

The imbalance occurred rather suddenly: about one year before the children became Nearsighted. For at least five years after the development of myopia, the eye kept becoming longer but the lens stopped flattening and thinning.

In contrast to the lens, changes in corneal growth showed little or no relation to the development of myopia. The cornea is responsible for about two-thirds of the optical power of the eye, and the lens for the remaining one-third.

The study provides vision professionals with an important new piece of information on why some children develop myopia. However, what's still unclear is why the lens suddenly stops adapting to continued growth of the eye. More research will be needed to answer that question -- one possibility is that an abnormally thick ciliary muscle within the eye forms a mechanical restriction preventing the stretching that thins and flattens the lens as the eye continues to grow.

http://www.sciencedaily.com/releases/2012/03/120301113258.htm

Story Source:

The above story is reprinted from materials provided by Wolters Kluwer Health: Lippincott Williams & Wilkins, via Newswise.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Glaucoma as Neurologic Disorder Rather Than Eye Disease?

 

ScienceDaily (Mar. 7, 2012) - A new paradigm to explain Glaucoma is rapidly emerging, and it is generating brain-based treatment advances that may ultimately vanquish the disease known as the "sneak thief of sight." A review now available in Ophthalmology, the journal of the American Academy of Ophthalmology, reports that some top researchers no longer think of Glaucoma solely as an eye disease. Instead, they view it as a neurologic disorder that causes nerve cells in the brain to degenerate and die, similar to what occurs in Parkinson disease and in Alzheimer's. The review, led by Jeffrey L Goldberg, M.D., Ph.D., assistant professor of ophthalmology at the Bascom Palmer Eye Institute and Interdisciplinary Stem Cell Institute, describes treatment advances that are either being tested in patients or are scheduled to begin clinical trials soon.

Glaucoma is the most common cause of irreversible blindness worldwide. For many years, the prevailing theory was that vision damage in Glaucoma patients was caused by abnormally high pressure inside the eye, known as intraocular pressure (IOP). As a result, lowering IOP was the only goal of those who developed surgical techniques and medications to treat Glaucoma. Creating tests and instruments to measure and track IOP was crucial to that effort. Today, a patient's IOP is no longer the only measurement an ophthalmologist uses to diagnose Glaucoma, although it is still a key part of deciding how to care for the patient. IOP-lowering medications and surgical techniques continue to be effective ways to protect Glaucoma patients' eyes and vision. Tracking changes in IOP over time informs the doctor whether the treatment plan is working.

But even when surgery or medication successfully lowers IOP, vision loss continues in some Glaucoma patients. Also, some patients find it difficult to use eye drop medications as prescribed by their physicians. These significant shortcomings spurred researchers to look beyond IOP as a cause of Glaucoma and focus of treatment.

The new research paradigm focuses on the damage that occurs in a type of nerve cell called retinal ganglion cells (RGCs), which are vital to the ability to see. These cells connect the eye to the brain through the optic nerve.

RGC-targeted Glaucoma treatments now in clinical trials include: medications injected into the eye that deliver survival and growth factors to RGCs; medications known to be useful for stroke and Alzheimer's, such as cytidine-5-diphosphocholine; and electrical stimulation of RGCs, delivered via tiny electrodes implanted in contact lenses or other external devices. Human trials of stem cell therapies are in the planning stages.

"As researchers turn their attention to the mechanisms that cause retinal ganglion cells to degenerate and die, they are discovering ways to protect, enhance and even regenerate these vital cells," said Dr. Goldberg. "Understanding how to prevent damage and improve healthy function in these neurons may ultimately lead to sight-saving treatments for Glaucoma and other degenerative eye diseases."

If this neurologically-based research succeeds, future Glaucoma treatments may not only prevent Glaucoma from stealing patients' eyesight, but may actually restore vision. Scientists also hope that their in-depth exploration of RGCs will help them determine what factors, such as genetics, make some people more vulnerable to Glaucoma.

http://www.sciencedaily.com/releases/2012/03/120307094659.htm

Story Source:

The above story is reprinted from materials provided by American Academy of Ophthalmology.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

New Treatment For Age-Related Macular Degeneration Within Sight

With 8 million people at high risk for advanced age-related Macular Degeneration, researchers from Harvard and Japan discovered that the experimental drug, endostatin, may be the cure. A research report  describes how giving endostatin to mice significantly reduced or eliminated abnormal blood vessel growth within the eye, which is ultimately why the disease causes blindness.

"Our study provides intriguing findings that may lead to a better treatment of age-related Macular Degeneration," said Alexander Marneros, the first author of the report, "but clinical studies in patients with age-related Macular Degeneration are still necessary."

In this study, researchers describe testing the effects of endostatin on mice lacking this naturally occurring substance. The mice without endostatin were about three times more likely to develop advanced age-related Macular Degeneration (AMD) than normal mice. Then the researchers administered endostatin to both sets of mice. In the mice lacking endostatin, the number of abnormal blood vessels that cause AMD were reduced to normal levels. In control mice with normal levels of endostatin, the number of abnormal blood vessels were practically undetectable.

"With Baby Boomers reaching advanced ages, new treatments are desperately needed to keep age-related Macular Degeneration from becoming a national epidemic," said Gerald Weissmann, MD, Editor-in-Chief of The FASEB Journal. "This research provides hope for those at risk for blindness, and it gives everyone another glimpse of how investments in molecular biology will ultimately pay off in terms of new treatments and cures."

AMD is a progressive disease that affects the part of the eye that allows people to see fine details. The disease gradually destroys sharp, central vision, and in advanced stages ultimately leads to total blindness. Abnormal blood vessel growth, also known as angiogenesis, is a hallmark of advanced AMD. These faulty blood vessels leak fluids and blood, causing catastrophic vision loss.

As the name implies, risk for age-related Macular Degeneration increases with age, and 8 million people are considered to be at high risk for the disease. Of these individuals, approximately 1 to 1.3 million will develop advanced AMD within the next five years. Endostatin is an experimental drug, which is currently being tested to stop cancer in people by restricting the formation of abnormal blood vessels supply blood to tumors. Endostatin is a protein in collagen, and while collagen is used in a range of products for skin care to gelatin desserts, consumption or use of these products does not have any effect on tumors or AMD.

Weissmann added, "This research proves once and for all that endostatin functions as the body's own natural inhibitor of new blood vessel growth as Judah Folkman of Harvard predicted."

This research was published in the December 2007 issue of The FASEB Journal.

http://www.sciencedaily.com/releases/2007/11/071129142449.htm

Story Source:

The above story is reprinted from materials provided by Federation of American Societies for Experimental Biology, via EurekAlert!, a service of AAAS.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Laser's Precision and Simplicity Could Revolutionize Cataract Surgery

 

Two new studies add to the growing body of evidence that a new approach to Cataract surgery may be safer and more efficient than today's standard procedure. The new approach, using a special femtosecond laser, is FDA-approved, but not yet widely available in the United States. It's one of the hottest topics this week at the 115th Annual Meeting of the American Academy of Ophthalmology.

Research reported Oct. 23 by William W. Culbertson, MD, of the Bascom Palmer Eye Institute at the University of Miami School of Medicine, and by Mark Packer, MD, of Oregon Health and Sciences University, confirms several advantages of laser Cataract surgery.

Laser Lens Fragmentation Boost Safety by Reducing Need for Ultrasound

Dr. Culbertson's team studied how pre-treating Cataracts with the femtosecond laser affected the level of ultrasound energy needed to soften the Cataracts. This emulsification is performed so that the Cataracts can be easily suctioned out. Surgeons want to use the lowest possible level of ultrasound energy, since in a small percentage of patients it is associated with slower recovery of good vision after surgery and/or problems with the cornea, which is the clear outer layer of the eye. Ideally, in appropriate cases, ultrasound use would be eliminated altogether.

In Dr. Culbertson's prospective, randomized study, 29 patients had laser Cataract surgery with a femtosecond laser in one eye and the standard Cataract procedure, called phacoemulsification, in the other. Laser surgery included: a laser capsulotomy, which is a circular incision in the lens capsule, followed by laser lens fragmentation, then ultrasound emulsification and aspiration. Lens fragmentation involved using the laser to split the lens into sections and then soften it by etching cross-hatch patterns on its surface. Standard surgery included a manual incision, followed by ultrasound emulsification and aspiration. After Cataract removal by either method, intraocular lenses were inserted into eyes to replace the natural lens and provide appropriate vision correction for each patient.

The use of ultrasound energy use was reduced by 45 percent in the laser pre-treated eyes compared with the eyes that received the standard cataract surgery procedure. Also, surgical manipulation of the eye was reduced by 45 percent in eyes that received laser pre-treatment as compared to manual standard surgery. This study involved the most common types of cataracts, those graded 1- 4. Dr. Culbertson notes that these findings may not apply to higher grade cataracts.

"In clinical practice, surgeons would expect safer, faster cataract surgery when laser pre-treatment is performed before cataract removal," said Dr. Culbertson. "The combination of precision and simplification that is possible with the femtosecond laser represents a major advance for this surgery."

Laser Lens Fragmentation Protects Corneal Endothelial Cells

Dr. Packer's team at the Oregon Health and Sciences University in Portland, Oregon, assessed the safety of laser cataract surgery in terms of loss of corneal endothelial cells, as measured after cataract surgery. Measuring endothelial cell loss is one of the most important ways to assess the safety of new cataract surgery techniques and technology. These cells preserve the cornea's clarity, and since they don't regenerate, they must last a lifetime. Dr. Packer's study found that when laser lens fragmentation was used in 225 eyes, there was no loss of endothelial cells, while the 63 eyes that received standard treatment had cell loss of one to seven percent.

"Our finding, that laser lens fragmentation appears to protect corneal endothelial cells, represents a significant benefit of this new surgery," said Dr. Packer. "This procedure is safer than standard cataract treatment and is likely to mean better vision and fewer eye health concerns for cataract patients, over the long term."

Earlier studies of femtosecond laser cataract surgery found other benefits. The laser allows the surgeon to make smaller, more precise incisions and to perform improved capsulotomies, which is the removal of part of the lens capsule that make intraocular lens (IOL) placement more secure. This reduces the chance that an IOL will later become displaced. Also, laser cataract surgery appears to improve results in patients who opt for advanced technology IOLs, plus corrective corneal incisions, to achieve good all-distance vision.

Femtosecond lasers have been used by ophthalmologists for years in refractive surgery such as LASIK, in-corneal transplants, and in other procedures. In 2009, a new type of femtosecond laser that could reach deep enough into the eye to be used in cataract removal was approved by the FDA. In addition to Dr. Culbertson's and Dr. Packer's presentations, key sessions on the topic at the Academy's 2011 Annual Meeting include a special session in the Sunday afternoon program, Spotlight on Femtosecond-Assisted Cataract Surgery: The Tough Questions, Femtosecond Laser Cataract Surgery: the Future,a video presentation,and two new instruction courses.

http://www.sciencedaily.com/releases/2011/10/111023135653.htm

Story Source:

The above story is reprinted from materials provided by American Academy of Ophthalmology.

Note: Materials may be edited for content and length. For further information, please contact the source cited above

Detecting Glaucoma Before It Blinds

 

Early detection and diagnosis of open angle Glaucoma important so that treatment can be used in the early stages of the disease developing to prevent or avoid further vision loss. Writing in a forthcoming issue of the International Journal of Medical Engineering and Informatics, researchers in the US have analyzed and ranked the various risk factors for open angle Glaucoma so that patients can be screened at an earlier stage if they are more likely to develop the condition.

Glaucoma is one of the main leading causes of blindness; it is a progressive and irreversible disease. Of the various forms of Glaucoma, open angle Glaucoma (OAG) is the most common and can cause the most damage. Unfortunately, unless a patient is undergoing regular screening from about the age of 40 years because of a family history, it is otherwise difficult to detect until substantial and irreversible vision loss has occurred. Glaucoma is the third leading cause of blindness worldwide and the second leading cause of blindness in the USA.

Now, Duo Zhou and colleagues at the University of Medicine and Dentistry of New Jersey, Newark, have used statistical collinearity analysis to evaluate risk factors for OAG, and logistic regression models to identify a minimum set of such risk factors for prognosis and diagnosis of the disease. Their study was based on more than 400 patients with subtle or severe vision problems who attended hospital. It reveals the relative risk of being a smoker, age, visual "field test" results, presence of a localized notch or thinning of the neuroretinal rim identified during standard eye examination, cup to disk ratio (a measure of restriction of the optic nerve at the back of the eye) and other factors.

The data are complex and separating out predictors from diagnostic factors was difficult, the team admits. However, they suggest that family history, medical history, current medications, geographic location, visual field test and ocular examination must all be considered in diagnosis and prognosis for OAG. They have excluded certain factors from the OAG prognosis: gender, race, family history of Glaucoma, diabetes mellitus, hypercholesterolemia, thyroid disease, migraine, Reynaud's disease and myopia as these have no direct effect on OAG development.

As revealed in the analyses, the odds of developing OAG will be increased by 91% with an increase in the Cup-to-Disc ratio of 0.1. Risk increases by 3% annually by age but decreases by 31% for every dB increase of mean deviation of Humphrey visual field. The odds of developing OAG will be 4.36 higher for patients with abnormal Humphrey visual filed overall test, 7.19 higher in patients with localized notch or thinning of the neuroretinal rim. Interestingly, patients with a smoking history seem to be less likely to develop OAG as compared to those with smoking history; although there are many smokers with OAG. Oddly, because of the location of the study, the team can also say that patients living in Atlantic/Quebec will be 73% less likely to develop OAG compared to their fellow Canadians in Ontario.

http://www.sciencedaily.com/releases/2011/10/111006094823.htm

Story Source:

The above story is reprinted from materials provided by Inderscience Publishers, via EurekAlert!, a service of AAAS.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Cornea Gene Discovery Reveals Why Humans See Clearly

ScienceDaily (Dec. 12, 2011) — A transparent Cornea is essential for vision, which is why the eye has evolved to nourish the Cornea without blood vessels. But for millions of people around the world, diseases of the eye or trauma spur the growth of blood vessels and can cause blindness.

A new Northwestern Medicine study has identified a gene that plays a major role in maintaining clarity of the Cornea in humans and mice -- and could possibly be used as gene therapy to treat diseases that cause blindness. The paper is published in the Proceedings of the National Academy of Sciences.

"We believe we've discovered the master regulator gene that prevents the formation of blood vessels in the eye and protects the clarity of the Cornea," said lead author Tsutomu Kume, associate professor of medicine at Northwestern University Feinberg School of Medicine and a researcher at Feinberg Cardiovascular Research Institute.

The existence of the gene, FoxC1, was previously known, but its role in maintaining a clear Cornea is a new finding. Working with a special breed of mice that are missing this gene, Kume and colleagues found abnormal vascular formations, or blood vessels, streaking their Corneas and blocking light.

When Kume discovered the Corneal blood vessels in the mutant mice, he called a collaborator at the University of Alberta in Canada, Ordan Lehmann, MD, professor of ophthalmology and medical genetics.

Lehmann found that his patients who have a single copy of this mutated FoxC1 gene -- and who have congenital glaucoma -- also have abnormal blood vessel growth in their eyes.

"The exciting thing is by showing the loss of FoxC1 causes vascularization of the Cornea, it means increasing levels of the gene might help prevent the abnormal growth of blood vessels, potentially in multiple eye disorders that cause blindness," said Lehmann, a coauthor on the paper. "That's the hope." One possible use might be in corneal transplants, he said, where the growth of new blood vessels onto the transplanted cornea is a major problem.

Kume next plans to test the gene therapy in mice to see if injecting FoxC1 inhibits the formation of blood vessels in the cornea.

The research is funded by National Institutes of Health and Canadian Institutes of Health Research.

http://www.sciencedaily.com/releases/2011/12/111212153121.htm

Story Source:

The above story is reprinted from materials provided by Northwestern University. The original article was written by Marla Paul.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Contact Lenses Provide Extended Pain Relief to Laser Eye Surgery Patients

ContactContact Lenses Provide Extended Pain Relief to Laser Eye Surgery Patients

Scientists are reporting development of ContactContact lenses that could provide a continuous supply of anesthetic medication to the eyes of patients who undergo laser eye surgery -- an advance that could relieve patients of the burden of repeatedly placing drops of medicine into their eyes every few hours for several days.Their report appears in ACS' journal Langmuir

.

Anuj Chauhan and colleagues explain that more than 1 million laser eye correction procedures are performed each year in the U.S. The surgery enables most patients to see clearly without eye glasses or ContactContact lenses. The procedure known as LASIK is the most common type of laser eye surgery, but complications can develop if the patient undergoes trauma or is hit very hard at any time after the procedure. Photorefractive keratectomy (PRK) doesn't have this complication, and that's why it is preferred for athletes and those in the military. A downside to PRK, however, is a longer period of pain after surgery. To ease their pain, PRK patients place drops of several medications, including anesthetics, into their eyes every few hours, which can interfere with daily life and increase the risk of drug overdose. PRK patients receive a special "bandage ContactContact lens" after surgery to help the outer layer of the eye heal.

The researchers tested whether anesthetics loaded onto this type of lens could release the drugs over time automatically. They found that adding vitamin E to the lenses extended the time of release of three commonly used anesthetics from just under two hours to up to an entire day -- or a few days in some instances. The vitamin E acts as a barrier, keeping the anesthetics on the eye, right where they are needed. The researchers say that, in the future, these lenses could serve as bandage ContactContact lenses after PRK surgery while also delivering necessary pain medications.

The authors acknowledge funding from the University of Florida.

http://www.sciencedaily.com/releases/2012/01/120118112001.htm

The above story is reprinted from materials provided by American Chemical Society.

Note: Materials may be edited for content and length. For further information, please ContactContact the source cited above.

New Glaucoma Test Allows Earlier, More Accurate Detection

Cumbersome Glaucoma tests that require a visit to the ophthalmologist could soon be history thanks to a home test developed by a UA engineer.

Phoenix ophthalmologist Dr. Gholan Peyman demonstrates a prototype Glaucoma test instrument that's noninvasive and simpler to use than current procedures. It can also be used in situations that are difficult or impossible with current tests. (Credit: Image courtesy of University of Arizona College of Engineering)

The self-test instrument has been designed in Eniko Enikov's lab at the UA College of Engineering. Gone are the eye drops and need for a sterilized sensor. In their place is an easy-to-use probe that gently rubs the eyelid and can be used at home.

"You simply close your eye and rub the eyelid like you might casually rub your eye," said Enikov, a professor of aerospace and mechanical engineering. "The instrument detects the stiffness and, therefore, infers the intraocular pressure." Enikov also heads the Advanced Micro and Nanosystems Laboratory.

While the probe is simple to use, the technology behind it is complex, involving a system of micro-force sensors, specially designed microchips, and math-based procedures programmed into its memory.

Enikov began working on the probe four years ago in collaboration with Dr. Gholan Peyman, a Phoenix ophthalmologist. "We went through several years of refinement and modifications to arrive at the current design," Enikov noted.

The National Science Foundation has funded the work, and Enikov and Peyman now are seeking investors to help fund final development and commercialization of the product.

In addition to screening for Glaucoma, an eye disease that can lead to blindness if left untreated, the device corrects some problems with the current procedure, and can be used to measure drainage of intraocular fluid.

"Eye pressure varies over a 24-hour cycle," Enikov said. "So it could be low at the doctor's office and three hours later it might be high. With only a single test, the doctor might miss the problem. Having the ability to take more frequent tests can lead to earlier detection in some cases."

Once the diagnosis is made, several treatments are available. The question then is: How effective are they? Patients could use the probe at home to trace how much the pressure decreases after using eye drop medications, for instance.

"One of the reasons pressure builds up in the eye is because fluid doesn't drain properly," Enikov noted. "Currently, there are no methods available to test drainage."

Current tests require applying pressure directly to the cornea, but only very light pressure is safe to use, and it doesn't cause the fluid to drain.

"Our technique allows us to apply slightly greater pressure, but it's still not uncomfortable," he said. "It's equivalent to rubbing your eye for a brief period to find out if the pressure changes. If it does, we know by how much and if there is a proper outflow of intraocular fluid."

Sometimes, a surgical shunt is used to help fluid drain from the eye. "The problem with Glaucoma shunts is they can plug up over time," Enikov noted. "Or if they're not properly installed, they may drain too quickly. So you would want to know how well the shunt is working and if it is properly installed. Our device could help answer those questions."

In another scenario, certain patients cannot be tested for Glaucoma using currently available procedures. "If a patient had cataract surgery or some other surgery through the cornea, the cornea sometimes thickens," Enikov said. "The cornea's structure is different, but our test remains accurate because it's not applied to the cornea."

Instead, it presses the entire eyeball, much as you might press a balloon to determine its stiffness.

"The innovation with our device is that it's noninvasive, simpler to use and applies to a variety of situations that are either difficult to address or impossible to test using the current procedures," Enikov said. "That's why we're so excited about this probe. It has great potential to improve medical care, and significant commercial possibilities, as well."

http://www.sciencedaily.com/releases/2011/01/110104101331.htm

The above story is reprinted from materials provided by University of Arizona College of Engineering. The original article was written by Ed Stiles.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

The Pupils Are the Windows to the Mind

The eyes are the window into the soul -- or at least the mind, according to a new paper published in Perspectives on Psychological Science, a journal of the Association for Psychological Science. Measuring the diameter of the Pupil, the part of the eye that changes size to let in more light, can show what a person is paying attention to. Pupillometry, as it's called, has been used in social psychology, clinical psychology, humans, animals, children, infants -- and it should be used even more, the authors say.

The Pupil is best known for changing size in reaction to light. In a dark room, your Pupils open wide to let in more light; as soon as you step outside into the sunlight, the Pupils shrink to pinpricks. This keeps the retina at the back of the eye from being overwhelmed by bright light. Something similar happens in response to psychological stimuli, says Bruno Laeng of the University of Oslo, who cowrote the paper with Sylvain Sirois of Université du Québec à Trois-Rivières and Gustaf Gredebäck of Uppsala University in Sweden. When someone sees something they want to pay closer attention to, the Pupil enlarges. It's not clear why this happens, Laeng says. "One idea is that, by essentially enlarging the field of the visual input, it's beneficial to visual exploration," he says.

However it works, psychological scientists can use the fact that people's Pupils widen when they see something they're interested in.

Laeng has used Pupil size to study people who had damage to the hippocampus, which usually causes very severe amnesia. Normally, if you show one of these patients a series of pictures, then take a short break, then show them another series of pictures, they don't know which ones they've seen before and which ones are new. But Laeng measured patients' Pupils while they did this test and found that the patients did actually respond differently to the pictures they had seen before. "In a way, this is good news, because it shows that some of the brains of these patients, unknown to themselves, is actually capable of making the distinction," he says.

Pupil measurement might also be useful for studying babies. Tiny infants can't tell you what they're paying attention to. "Developmental psychologists have used all kinds of methods to get this information without using language," Laeng says. Seeing what babies are interested in can give clues to what they're able to recognize -- different shapes or sounds, for example. A researcher might show a child two images side by side and see which one they look at for longer. Measuring the size of a baby's pupils could do the same without needing a comparison.

The technology already exists for measuring pupils -- many modern psychology studies use eye-tracking technology, for example, to see what a subject is looking at, and Laeng and his coauthors hope to convince other psychological scientists to use this method.

http://www.sciencedaily.com/releases/2012/01/120127162800.htm

The above story is reprinted from materials provided by Association for Psychological Science.